We are live on
!
Find out more
FCM
Frontier Capital Management Portfolio holdings
AUM
$9.73B
1-Year Est. Return
55.65%
This Fund
S&P 500
This Quarter
Est. Return
+14.42%
1 Year Est. Return
+55.65%
3 Year Est. Return
+154.46%
5 Year Est. Return
+213.15%
10 Year Est. Return
+1,202.39%
AUM
$10.4B
AUM Growth
+$767M
(+7.9%)
Cap. Flow
-$138M
Cap. Flow
% of AUM
-1.32%
Top 10 Holdings %
Top 10 Hldgs %
17.61%
Holding
276
New
19
Increased
78
Reduced
164
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Albemarle
ALB
|
+$60.1M |
| 2 |
MongoDB
MDB
|
+$57.2M |
| 3 |
Eagle Materials
EXP
|
+$53.2M |
| 4 |
BECN
Beacon Roofing Supply, Inc.
BECN
|
+$45.9M |
| 5 |
Steris
STE
|
+$43.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Genpact
G
|
+$119M |
| 2 |
Aon
AON
|
+$68.5M |
| 3 |
Humana
HUM
|
+$51.3M |
| 4 |
Okta
OKTA
|
+$48.5M |
| 5 |
SiTime
SITM
|
+$48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 24.25% |
| 2 | Technology | 23.2% |
| 3 | Healthcare | 15.2% |
| 4 | Consumer Discretionary | 13.23% |
| 5 | Financials | 8.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Supernus Pharmaceuticals
SUPN
$2.7B
| $6.09M | 0.06% |
202,653
-102,426
| -34% | -$3.58M |
|
227
Charles River Laboratories
CRL
$11.3B
| $5.75M | 0.06% |
27,336
-279
| -1% | -$55.5K |
|
228
Commault Systems
CVLT
$4.98B
| $5.7M | 0.05% |
78,436
-804
| -1% | -$52.3K |
|
229
Qiagen
QGEN
$8.62B
| $5.59M | 0.05% |
117,134
-1,199
| -1% | -$57.8K |
|
|
AZEK
230
DELISTED
The AZEK Co
AZEK
| $5.09M | 0.05% |
167,911
-1,724
| -1% | -$44.6K |
|
231
Avantor
AVTR
$9.82B
| $5.07M | 0.05% |
246,781
+99,696
| +68% | +$2.02M |
|
232
Jazz Pharmaceuticals
JAZZ
$16.1B
| $5.01M | 0.05% |
40,397
-19,146
| -32% | -$2.58M |
|
233
Upwork
UPWK
$1.18B
| $4.43M | 0.04% |
474,671
-640,056
| -57% | -$5.8M |
|
234
Planet Labs
PL
$6.94B
| $4.34M | 0.04% |
+1,349,132
| New | +$5.35M |
|
235
Incyte
INCY
$25.4B
| $4.27M | 0.04% |
68,597
-700
| -1% | -$46.8K |
|
236
Stratasys
SSYS
$666M
| $4.27M | 0.04% |
240,235
+67,585
| +39% | +$1.06M |
|
237
TPG
TPG
$6.76B
| $4.09M | 0.04% |
139,825
-1,431
| -1% | -$40.2K |
|
|
BASE
238
DELISTED
Couchbase
BASE
| $4.08M | 0.04% |
257,593
-16,530
| -6% | -$270K |
|
239
Tandem Diabetes Care
TNDM
$1.27B
| $3.61M | 0.03% |
147,293
-1,512
| -1% | -$48.6K |
|
240
SS&C Technologies
SSNC
$18.9B
| $3.53M | 0.03% |
58,310
-597
| -1% | -$33.9K |
|
241
Trupanion
TRUP
$1.13B
| $3.21M | 0.03% |
163,304
+9,787
| +6% | +$276K |
|
|
SGEN
242
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.1M | 0.03% |
16,091
-7
| -0% | -$1.39K |
|
243
Ranpak Holdings
PACK
$500M
| $2.78M | 0.03% |
615,034
+1,885
| +0.3% | +$7.49K |
|
|
CMRC
244
Commerce.com Inc Series 1
CMRC
$272M
| $2.74M | 0.03% |
275,355
+101,150
| +58% | +$843K |
|
|
TWOU
245
DELISTED
2U Inc
TWOU
| $2.64M | 0.03% |
21,815
-223
| -1% | -$29.7K |
|
246
Regal Rexnord
RRX
$12.5B
| $2.11M | 0.02% |
+13,678
| New | +$1.86M |
|
247
C3.ai
AI
$1.38B
| $2.08M | 0.02% |
57,173
-943,061
| -94% | -$26.6M |
|
248
Cardlytics
CDLX
$22.2M
| $2.02M | 0.02% |
31,894
-327
| -1% | -$19.8K |
|
249
Halozyme
HALO
$9.88B
| $1.64M | 0.02% |
+45,459
| New | +$1.55M |
|
250
Willdan Group
WLDN
$1.02B
| $1.63M | 0.02% |
85,286
-247,228
| -74% | -$4.16M |
|
Similar funds
HL
DCP
CCM
URS
CIM
MPI
TIM
DPIM
Frontier Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Frontier Capital Management held 276 positions worth $10.4B, up 7.9% from $9.67B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Frontier Capital Management's Q2 2023 filing shows 19 new, 78 increased, 164 reduced and 15 closed positions. Its largest new stake was Steris: 219,587 shares worth $49.4M. The largest sale was Genpact, an estimated $119M.
By sector, the portfolio is most concentrated in Industrials at 24% of assets, up from 20% a quarter earlier, followed by Technology and Healthcare.
- Frontier Capital Management's largest Q2 2023 buy was Steris: 219,587 shares worth $49.4M.
- Frontier Capital Management added most to Albemarle in Q2 2023, an estimated $60.1M increase.
- Frontier Capital Management's biggest Q2 2023 reduction was Genpact, cutting an estimated $119M.
- Frontier Capital Management fully exited Advance Auto Parts in Q2 2023, selling an estimated $40.1M.
- Frontier Capital Management's ten largest holdings make up 18% of its $10.4B portfolio in Q2 2023.
- Frontier Capital Management opened 19 new positions and closed 15 in Q2 2023.
- Frontier Capital Management's portfolio value rose 7.9% quarter-over-quarter to $10.4B.
Based on Frontier Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.